Want to see NVST full AI Analyst Report?

Envista Holdings (NVST) Stock Forecast & Price Target

200 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NVST Analyst Ratings

Moderate Buy

6 Buy

6 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Envista

Holdings

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NVST Stock 12 Month Forecast

Average Price Target

$30.40

▲(10.67% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Envista Holdings in the last 3 months. The average price target is $30.40 with a high forecast of $34.00 and a low forecast of $23.00. The average price target represents a 10.67% change from the last price of $27.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","23":"$23","27":"$27","31":"$31","35":"$35"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,23,27,31,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.64,27.206153846153846,27.77230769230769,28.338461538461537,28.904615384615386,29.470769230769232,30.036923076923078,30.603076923076923,31.16923076923077,31.735384615384618,32.30153846153846,32.86769230769231,33.433846153846154,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.64,26.92923076923077,27.21846153846154,27.50769230769231,27.796923076923076,28.086153846153845,28.375384615384615,28.664615384615384,28.953846153846154,29.243076923076924,29.53230769230769,29.82153846153846,30.11076923076923,{"y":30.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.64,26.36,26.080000000000002,25.8,25.52,25.240000000000002,24.96,24.68,24.4,24.12,23.84,23.560000000000002,23.28,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.77,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.26,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.44,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.33,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.37,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.17,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.31,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.64,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$34.00

Average Price Target$30.40

Lowest Price Target$23.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

09/02/26

Jason Bednar

Piper Sandler

$28

Hold

1.93%

Upside

Reiterated

09/01/26

Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), BioMarin Pharmaceutical (NASDAQ: BMRN) and Envista Holdings (NYSE: NVST)

Glen Santangelo

Barclays

$32

Buy

16.49%

Upside

Reiterated

08/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NYSE: NVST), Healthequity (NASDAQ: HQY) and Insight Molecular Diagnostics (NASDAQ: IMDX)

Daniel Grosslight

Citi

$32

Hold

16.49%

Upside

Reiterated

08/10/26

Envista Holdings (NVST) Gets a Hold from Citi

Erin Wright

Morgan Stanley

$21→$23

Hold

-16.27%

Downside

Assigned

08/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Envista Holdings (NYSE: NVST) and Elanco Animal Health (NYSE: ELAN)

Allen Lutz

Bank of America Securities

$34

Buy

23.77%

Upside

Reiterated

08/06/26

Envista: Buy Rating Reiterated as Execution Strengthens and 2026 Forecasts Raised; $34 Price Target Reaffirmed

Jeff Johnson

Robert W. Baird

$31→$34

Buy

23.77%

Upside

Reiterated

08/06/26

Envista price target raised to $34 from $31 at BairdEnvista price target raised to $34 from $31 at Baird

Jonathan Block

Stifel Nicolaus

$31

Buy

12.85%

Upside

Reiterated

08/06/26

Stifel Nicolaus Sticks to Their Buy Rating for Envista Holdings (NVST)

Elizabeth Anderson CFA

Evercore ISI

$32

Buy

16.49%

Upside

Reiterated

08/06/26

Evercore ISI Sticks to Its Buy Rating for Envista Holdings (NVST)

David Saxon

Needham

―

Hold

―

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Envista Holdings (NYSE: NVST) and Akebia Therapeutics (NASDAQ: AKBA)

Steven Valiquette

Mizuho Securities

$27→$29

Hold

5.57%

Upside

Reiterated

08/06/26

Envista price target raised to $29 from $27 at MizuhoEnvista price target raised to $29 from $27 at Mizuho

Vik Chopra

BMO Capital

$27→$29

Hold

5.57%

Upside

Reiterated

08/05/26

Envista Holdings (NVST) Gets a Hold from BMO Capital

Lilia-Celine (Lily) Lozada

J.P. Morgan

$26→$29

Hold

5.57%

Upside

Reiterated

05/07/26

Envista price target raised to $29 from $26 at JPMorganEnvista price target raised to $29 from $26 at JPMorgan

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

$21→$26

Hold

-5.35%

Downside

Reiterated

02/06/26

Wells Fargo Sticks to Its Hold Rating for Envista Holdings (NVST)

Michael Cherny

Leerink Partners

$35

Buy

27.41%

Upside

Upgraded

02/06/26

Envista upgraded to Outperform from Market Perform at LeerinkEnvista upgraded to Outperform from Market Perform at Leerink

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

09/02/26

Jason Bednar

Piper Sandler

$28

Hold

1.93%

Upside

Reiterated

09/01/26

Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), BioMarin Pharmaceutical (NASDAQ: BMRN) and Envista Holdings (NYSE: NVST)

Glen Santangelo

Barclays

$32

Buy

16.49%

Upside

Reiterated

08/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NYSE: NVST), Healthequity (NASDAQ: HQY) and Insight Molecular Diagnostics (NASDAQ: IMDX)

Daniel Grosslight

Citi

$32

Hold

16.49%

Upside

Reiterated

08/10/26

Envista Holdings (NVST) Gets a Hold from Citi

Erin Wright

Morgan Stanley

$21→$23

Hold

-16.27%

Downside

Assigned

08/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Envista Holdings (NYSE: NVST) and Elanco Animal Health (NYSE: ELAN)

Allen Lutz

Bank of America Securities

$34

Buy

23.77%

Upside

Reiterated

08/06/26

Envista: Buy Rating Reiterated as Execution Strengthens and 2026 Forecasts Raised; $34 Price Target Reaffirmed

Jeff Johnson

Robert W. Baird

$31→$34

Buy

23.77%

Upside

Reiterated

08/06/26

Envista price target raised to $34 from $31 at BairdEnvista price target raised to $34 from $31 at Baird

Jonathan Block

Stifel Nicolaus

$31

Buy

12.85%

Upside

Reiterated

08/06/26

Stifel Nicolaus Sticks to Their Buy Rating for Envista Holdings (NVST)

Elizabeth Anderson CFA

Evercore ISI

$32

Buy

16.49%

Upside

Reiterated

08/06/26

Evercore ISI Sticks to Its Buy Rating for Envista Holdings (NVST)

David Saxon

Needham

―

Hold

―

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Envista Holdings (NYSE: NVST) and Akebia Therapeutics (NASDAQ: AKBA)

Steven Valiquette

Mizuho Securities

$27→$29

Hold

5.57%

Upside

Reiterated

08/06/26

Envista price target raised to $29 from $27 at MizuhoEnvista price target raised to $29 from $27 at Mizuho

Vik Chopra

BMO Capital

$27→$29

Hold

5.57%

Upside

Reiterated

08/05/26

Envista Holdings (NVST) Gets a Hold from BMO Capital

Lilia-Celine (Lily) Lozada

J.P. Morgan

$26→$29

Hold

5.57%

Upside

Reiterated

05/07/26

Envista price target raised to $29 from $26 at JPMorganEnvista price target raised to $29 from $26 at JPMorgan

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

$21→$26

Hold

-5.35%

Downside

Reiterated

02/06/26

Wells Fargo Sticks to Its Hold Rating for Envista Holdings (NVST)

Michael Cherny

Leerink Partners

$35

Buy

27.41%

Upside

Upgraded

02/06/26

Envista upgraded to Outperform from Market Perform at LeerinkEnvista upgraded to Outperform from Market Perform at Leerink

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Envista Holdings

3 Months

Allen LutzBank of America Securities

Success Rate

10/17 ratings generated profit

Average Return

+2.97%

Copying Allen Lutz's trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +2.97% per trade.

1 Year

Allen LutzBank of America Securities

Success Rate

11/17 ratings generated profit

Average Return

+19.68%

Copying Allen Lutz's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +19.68% per trade.

2 Years

Allen LutzBank of America Securities

Success Rate

13/17 ratings generated profit

Average Return

+31.05%

Copying Allen Lutz's trades and holding each position for 2 Years would result in 76.47% of your transactions generating a profit, with an average return of +31.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVST Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NVST has received 9 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. NVST average Analyst price target in the past 3 months is 30.40.

Each month's total comprises the sum of three months' worth of ratings.

NVST Financial Forecast

NVST Earnings Forecast

Next quarter’s earnings estimate for NVST is $0.36 with a range of $0.35 to $0.38. The previous quarter’s EPS was $0.41. NVST beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NVST has Performed in-line its overall industry.

NVST Sales Forecast

Next quarter’s sales forecast for NVST is $695.84M with a range of $688.00M to $703.60M. The previous quarter’s sales results were $730.50M. NVST beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NVST has Performed in-line its overall industry.

NVST Stock Forecast FAQ

What is NVST’s average 12-month price target, according to analysts?

Based on analyst ratings, Envista Holdings Corp’s 12-month average price target is 30.40.

What is NVST’s upside potential, based on the analysts’ average price target?

Envista Holdings Corp has 10.67% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NVST a Buy, Sell or Hold?

Envista Holdings Corp has a consensus rating of Moderate Buy which is based on 6 buy ratings, 6 hold ratings and 0 sell ratings.

What is Envista Holdings Corp’s price target?

The average price target for Envista Holdings Corp is 30.40. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $34.00 ,the lowest forecast is $23.00. The average price target represents 10.67% Increase from the current price of $27.47.

What do analysts say about Envista Holdings Corp?

Envista Holdings Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of NVST?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Envista Holdings (NVST) Stock Forecast & Price Target

NVST Analyst Ratings

NVST Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Envista Holdings

NVST Analyst Recommendation Trends

NVST Financial Forecast

NVST Earnings Forecast

NVST Sales Forecast

NVST Stock Forecast FAQ

Detailed List of Analyst Forecasts